Stem cell transplant for aggressive leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a specific transplant method using a half-matched donor to treat high-risk acute myeloid leukemia (AML), a type of blood cancer. It aims to reduce complications and improve outcomes for patients who have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML), a blood cancer, that is high-risk or has not gone into remission after treatment.
- You have a suitable donor: a young male (under 30) or a female who has been pregnant, and the donor's blood type markers are a partial match (5/10 to 7/10).
- You are willing to receive a transplant using a specific drug combination (ATG and PTCy) to prevent graft-versus-host disease, a common transplant complication.
- You do not have active leukemia outside the bone marrow (like in the brain or skin) at the time of transplant.
- Your AML is not low or intermediate risk (you are in a high-risk category).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial tests a stem cell transplant from a matched sibling donor, followed by extra immune cells to help prevent relapse in people with high-risk acute myeloid leukemia (AML) who are in remission. It aims to improve outcomes by boosting the immune system's ability to fight any remaining leukemia cells.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This study compares two approaches for adults with high-risk acute myeloid leukemia (AML) who have had one round of chemo. One option is a stem cell transplant from a donor (using someone else's cells to rebuild your bone marrow), and the other is more chemotherapy or other treatments. The goal is to see which approach works better for people like you.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
Hear when a new High Risk Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.